1. Stuber M, Botnar RM, Fischer SE, et al. Preliminary report on in vivo coronary MRA at 3 Tesla in humans. Magn Reson Med. 2002; 48:425–429.
4. Plein S, Ryf S, Schwitter J, Radjenovic A, Boesiger P, Kozerke S. Dynamic contrast-enhanced myocardial perfusion MRI accelerated with k-t sense. Magn Reson Med. 2007; 58:777–785.
5. Cheng AS, Pegg TJ, Karamitsos TD, et al. Cardiovascular magnetic resonance perfusion imaging at 3-tesla for the detection of coronary artery disease: a comparison with 1.5-tesla. J Am Coll Cardiol. 2007; 49:2440–2449.
6. Patel AR, Kramer CM. Role of cardiac magnetic resonance in the diagnosis and prognosis of nonischemic cardiomyopathy. JACC Cardiovasc Imaging. 2017; 10:1180–1193.
7. Hundley WG, Bluemke DA, Finn JP, et al. ACCF/ACR/AHA/NASCI/SCMR 2010 expert consensus document on cardiovascular magnetic resonance: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents. J Am Coll Cardiol. 2010; 55:2614–2662.
10. Puntmann VO, Carr-White G, Jabbour A, et al. Native T1 and ECV of noninfarcted myocardium and outcome in patients with coronary artery disease. J Am Coll Cardiol. 2018; 71:766–778.
13. Mavrogeni S, Apostolou D, Argyriou P, et al. T1 and T2 mapping in cardiology: “mapping the obscure object of desire”. Cardiology. 2017; 138:207–217.
14. Kammerlander AA, Marzluf BA, Zotter-Tufaro C, et al. T1 mapping by CMR imaging: from histological validation to clinical implication. JACC Cardiovasc Imaging. 2016; 9:14–23.
15. Sado DM, Flett AS, Banypersad SM, et al. Cardiovascular magnetic resonance measurement of myocardial extracellular volume in health and disease. Heart. 2012; 98:1436–1441.
16. Dass S, Suttie JJ, Piechnik SK, et al. Myocardial tissue characterization using magnetic resonance noncontrast T1 mapping in hypertrophic and dilated cardiomyopathy. Circ Cardiovasc Imaging. 2012; 5:726–733.
17. Hinojar R, Varma N, Child N, et al. T1 mapping in discrimination of hypertrophic phenotypes: hypertensive heart disease and hypertrophic cardiomyopathy: findings from the international T1 multicenter cardiovascular magnetic resonance study. Circ Cardiovasc Imaging. 2015; 8:8.
![crossref](/image/icon/bnr_ref_cross.gif)
18. Puntmann VO, Voigt T, Chen Z, et al. Native T1 mapping in differentiation of normal myocardium from diffuse disease in hypertrophic and dilated cardiomyopathy. JACC Cardiovasc Imaging. 2013; 6:475–484.
19. Dweck MR, Puntman V, Vesey AT, Fayad ZA, Nagel E. MR imaging of coronary arteries and plaques. JACC Cardiovasc Imaging. 2016; 9:306–316.
21. Thavendiranathan P, Walls M, Giri S, et al. Improved detection of myocardial involvement in acute inflammatory cardiomyopathies using T2 mapping. Circ Cardiovasc Imaging. 2012; 5:102–110.
22. Usman AA, Taimen K, Wasielewski M, et al. Cardiac magnetic resonance T2 mapping in the monitoring and follow-up of acute cardiac transplant rejection: a pilot study. Circ Cardiovasc Imaging. 2012; 5:782–790.
23. Friedrich MG, Abdel-Aty H, Taylor A, Schulz-Menger J, Messroghli D, Dietz R. The salvaged area at risk in reperfused acute myocardial infarction as visualized by cardiovascular magnetic resonance. J Am Coll Cardiol. 2008; 51:1581–1587.
26. McAlindon EJ, Pufulete M, Harris JM, et al. Measurement of myocardium at risk with cardiovascular MR: comparison of techniques for edema imaging. Radiology. 2015; 275:61–70.
![crossref](/image/icon/bnr_ref_cross.gif)
27. Bohnen S, Radunski UK, Lund GK, et al. Performance of T1 and T2 mapping cardiovascular magnetic resonance to detect active myocarditis in patients with recent-onset heart failure. Circ Cardiovasc Imaging. 2015; 8:8.
![crossref](/image/icon/bnr_ref_cross.gif)
28. Verbrugge FH, Bertrand PB, Willems E, et al. Global myocardial oedema in advanced decompensated heart failure. Eur Heart J Cardiovasc Imaging. 2017; 18:787–794.
29. Friedrich MG. Myocardial edema--a new clinical entity? Nat Rev Cardiol. 2010; 7:292–296.
30. Giri S, Shah S, Xue H, et al. Myocardial T2 mapping with respiratory navigator and automatic nonrigid motion correction. Magn Reson Med. 2012; 68:1570–1578.
31. von Knobelsdorff-Brenkenhoff F, Prothmann M, Dieringer MA, et al. Myocardial T1 and T2 mapping at 3 T: reference values, influencing factors and implications. J Cardiovasc Magn Reson. 2013; 15:53.
33. Dweck MR, Williams MC, Moss AJ, Newby DE, Fayad ZA. Computed tomography and cardiac magnetic resonance in ischemic heart disease. J Am Coll Cardiol. 2016; 68:2201–2216.
34. McCrohon JA, Moon JC, Prasad SK, et al. Differentiation of heart failure related to dilated cardiomyopathy and coronary artery disease using gadolinium-enhanced cardiovascular magnetic resonance. Circulation. 2003; 108:54–59.
![crossref](/image/icon/bnr_ref_cross.gif)
35. Kwong RY, Chan AK, Brown KA, et al. Impact of unrecognized myocardial scar detected by cardiac magnetic resonance imaging on event-free survival in patients presenting with signs or symptoms of coronary artery disease. Circulation. 2006; 113:2733–2743.
37. Kim RJ, Wu E, Rafael A, et al. The use of contrast-enhanced magnetic resonance imaging to identify reversible myocardial dysfunction. N Engl J Med. 2000; 343:1445–1453.
38. Gutberlet M, Fröhlich M, Mehl S, et al. Myocardial viability assessment in patients with highly impaired left ventricular function: comparison of delayed enhancement, dobutamine stress MRI, end-diastolic wall thickness, and TI201-SPECT with functional recovery after revascularization. Eur Radiol. 2005; 15:872–880.
39. Leong DP, Chakrabarty A, Shipp N, et al. Effects of myocardial fibrosis and ventricular dyssynchrony on response to therapy in new-presentation idiopathic dilated cardiomyopathy: insights from cardiovascular magnetic resonance and echocardiography. Eur Heart J. 2012; 33:640–648.
40. Bodí V, Sanchis J, López-Lereu MP, et al. Usefulness of a comprehensive cardiovascular magnetic resonance imaging assessment for predicting recovery of left ventricular wall motion in the setting of myocardial stunning. J Am Coll Cardiol. 2005; 46:1747–1752.
41. Iles LM, Ellims AH, Llewellyn H, et al. Histological validation of cardiac magnetic resonance analysis of regional and diffuse interstitial myocardial fibrosis. Eur Heart J Cardiovasc Imaging. 2015; 16:14–22.
42. Kim RJ, Fieno DS, Parrish TB, et al. Relationship of MRI delayed contrast enhancement to irreversible injury, infarct age, and contractile function. Circulation. 1999; 100:1992–2002.
43. Garrido L, Wedeen VJ, Kwong KK, Spencer UM, Kantor HL. Anisotropy of water diffusion in the myocardium of the rat. Circ Res. 1994; 74:789–793.
44. Mekkaoui C, Reese TG, Jackowski MP, Bhat H, Sosnovik DE. Diffusion MRI in the heart. NMR Biomed. 2017; 30:30.
![crossref](/image/icon/bnr_ref_cross.gif)
46. Walker JC, Guccione JM, Jiang Y, et al. Helical myofiber orientation after myocardial infarction and left ventricular surgical restoration in sheep. J Thorac Cardiovasc Surg. 2005; 129:382–390.
47. Chen Y, Ye L, Zhong J, et al. The structural basis of functional improvement in response to human umbilical cord blood stem cell transplantation in hearts with postinfarct LV remodeling. Cell Transplant. 2015; 24:971–983.
50. Nielles-Vallespin S, Mekkaoui C, Gatehouse P, et al. In vivo diffusion tensor MRI of the human heart: reproducibility of breath-hold and navigator-based approaches. Magn Reson Med. 2013; 70:454–465.
51. Nguyen C, Fan Z, Sharif B, et al. In vivo three-dimensional high resolution cardiac diffusion-weighted MRI: a motion compensated diffusion-prepared balanced steady-state free precession approach. Magn Reson Med. 2014; 72:1257–1267.
52. Aliotta E, Wu HH, Ennis DB. Convex optimized diffusion encoding (CODE) gradient waveforms for minimum echo time and bulk motion-compensated diffusion-weighted MRI. Magn Reson Med. 2017; 77:717–729.
53. Nguyen C, Lu M, Fan Z, et al. Contrast-free detection of myocardial fibrosis in hypertrophic cardiomyopathy patients with diffusion-weighted cardiovascular magnetic resonance. J Cardiovasc Magn Reson. 2015; 17:107.
![crossref](/image/icon/bnr_ref_cross.gif)
55. Gilbert SH, Benoist D, Benson AP, et al. Visualization and quantification of whole rat heart laminar structure using high-spatial resolution contrast-enhanced MRI. Am J Physiol Heart Circ Physiol. 2012; 302:H287–H298.
![crossref](/image/icon/bnr_ref_cross.gif)
59. Doenst T, Nguyen TD, Abel ED. Cardiac metabolism in heart failure: implications beyond ATP production. Circ Res. 2013; 113:709–724.
60. Reibel DK, Rovetto MJ. Myocardial ATP synthesis and mechanical function following oxygen deficiency. Am J Physiol. 1978; 234:H620–H624.
![crossref](/image/icon/bnr_ref_cross.gif)
61. Garlid KD, Dos Santos P, Xie ZJ, Costa AD, Paucek P. Mitochondrial potassium transport: the role of the mitochondrial ATP-sensitive K(+) channel in cardiac function and cardioprotection. Biochim Biophys Acta. 2003; 1606:1–21.
62. Dzeja PP, Redfield MM, Burnett JC, Terzic A. Failing energetics in failing hearts. Curr Cardiol Rep. 2000; 2:212–217.
63. Zhou J, Payen JF, Wilson DA, Traystman RJ, van Zijl PC. Using the amide proton signals of intracellular proteins and peptides to detect pH effects in MRI. Nat Med. 2003; 9:1085–1090.
64. Gilad AA, McMahon MT, Walczak P, et al. Artificial reporter gene providing MRI contrast based on proton exchange. Nat Biotechnol. 2007; 25:217–219.
67. Zhou Z, Nguyen C, Chen Y, et al. Optimized CEST cardiovascular magnetic resonance for assessment of metabolic activity in the heart. J Cardiovasc Magn Reson. 2017; 19:95.
![crossref](/image/icon/bnr_ref_cross.gif)
68. Salerno M. Feature tracking by CMR: a “double feature”? JACC Cardiovasc Imaging. 2018; 11:206–208.
69. Vo HQ, Marwick TH, Negishi K. MRI-derived myocardial strain measures in normal subjects. JACC Cardiovasc Imaging. 2018; 11:196–205.
70. Ogawa R, Kido T, Nakamura M, et al. Diagnostic capability of feature-tracking cardiovascular magnetic resonance to detect infarcted segments: a comparison with tagged magnetic resonance and wall thickening analysis. Clin Radiol. 2017; 72:828–834.
71. Regenfus M, Ropers D, Achenbach S, et al. Noninvasive detection of coronary artery stenosis using contrast-enhanced three-dimensional breath-hold magnetic resonance coronary angiography. J Am Coll Cardiol. 2000; 36:44–50.
72. Grobner T, Prischl FC. Gadolinium and nephrogenic systemic fibrosis. Kidney Int. 2007; 72:260–264.
73. Kim WY, Danias PG, Stuber M, et al. Coronary magnetic resonance angiography for the detection of coronary stenoses. N Engl J Med. 2001; 345:1863–1869.
74. Schuetz GM, Zacharopoulou NM, Schlattmann P, Dewey M. Meta-analysis: noninvasive coronary angiography using computed tomography versus magnetic resonance imaging. Ann Intern Med. 2010; 152:167–177.
75. Jahnke C, Paetsch I, Nehrke K, et al. Rapid and complete coronary arterial tree visualization with magnetic resonance imaging: feasibility and diagnostic performance. Eur Heart J. 2005; 26:2313–2319.
76. Di Leo G, Fisci E, Secchi F, et al. Diagnostic accuracy of magnetic resonance angiography for detection of coronary artery disease: a systematic review and meta-analysis. Eur Radiol. 2016; 26:3706–3718.
77. Yonezawa M, Nagata M, Kitagawa K, et al. Quantitative analysis of 1.5-T whole-heart coronary MR angiograms obtained with 32-channel cardiac coils: a comparison with conventional quantitative coronary angiography. Radiology. 2014; 271:356–364.
78. Andia ME, Henningsson M, Hussain T, et al. Flow-independent 3D whole-heart vessel wall imaging using an interleaved T2-preparation acquisition. Magn Reson Med. 2013; 69:150–157.
79. Fayad ZA, Fuster V, Fallon JT, et al. Noninvasive in vivo human coronary artery lumen and wall imaging using black-blood magnetic resonance imaging. Circulation. 2000; 102:506–510.
80. Xie G, Bi X, Liu J, et al. Three-dimensional coronary dark-blood interleaved with gray-blood (cDIG) magnetic resonance imaging at 3 tesla. Magn Reson Med. 2016; 75:997–1007.
81. Desai MY, Lai S, Barmet C, Weiss RG, Stuber M. Reproducibility of 3D free-breathing magnetic resonance coronary vessel wall imaging. Eur Heart J. 2005; 26:2320–2324.
82. Gerretsen S, Kessels AG, Nelemans PJ, et al. Detection of coronary plaques using MR coronary vessel wall imaging: validation of findings with intravascular ultrasound. Eur Radiol. 2013; 23:115–124.
83. He Y, Zhang Z, Dai Q, et al. Accuracy of MRI to identify the coronary artery plaque: a comparative study with intravascular ultrasound. J Magn Reson Imaging. 2012; 35:72–78.
84. Miao C, Chen S, Macedo R, et al. Positive remodeling of the coronary arteries detected by magnetic resonance imaging in an asymptomatic population: MESA (Multi-Ethnic Study of Atherosclerosis). J Am Coll Cardiol. 2009; 53:1708–1715.
85. Puchner SB, Liu T, Mayrhofer T, et al. High-risk plaque detected on coronary CT angiography predicts acute coronary syndromes independent of significant stenosis in acute chest pain: results from the ROMICAT-II trial. J Am Coll Cardiol. 2014; 64:684–692.
86. Naghavi M, Libby P, Falk E, et al. From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: part I. Circulation. 2003; 108:1664–1672.
87. Kolodgie FD, Gold HK, Burke AP, et al. Intraplaque hemorrhage and progression of coronary atheroma. N Engl J Med. 2003; 349:2316–2325.
88. Noguchi T, Kawasaki T, Tanaka A, et al. High-intensity signals in coronary plaques on noncontrast T1-weighted magnetic resonance imaging as a novel determinant of coronary events. J Am Coll Cardiol. 2014; 63:989–999.
![crossref](/image/icon/bnr_ref_cross.gif)
89. Noguchi T, Tanaka A, Kawasaki T, et al. Effect of intensive statin therapy on coronary high-intensity plaques detected by noncontrast T1-weighted imaging: the AQUAMARINE pilot study. J Am Coll Cardiol. 2015; 66:245–256.
90. Xie Y, Kim YJ, Pang J, et al. Coronary atherosclerosis T1-weighed characterization with integrated anatomical reference: comparison with high-risk plaque features detected by invasive coronary imaging. JACC Cardiovasc Imaging. 2017; 10:637–648.
91. Pijls NH, Van Gelder B, Van der Voort P, et al. Fractional flow reserve. A useful index to evaluate the influence of an epicardial coronary stenosis on myocardial blood flow. Circulation. 1995; 92:3183–3193.
92. Sen S, Escaned J, Malik IS, et al. Development and validation of a new adenosine-independent index of stenosis severity from coronary wave-intensity analysis: results of the ADVISE (ADenosine Vasodilator Independent Stenosis Evaluation) study. J Am Coll Cardiol. 2012; 59:1392–1402.
93. Escaned J, Echavarría-Pinto M, Garcia-Garcia HM, et al. Prospective assessment of the diagnostic accuracy of instantaneous wave-free ratio to assess coronary stenosis relevance: results of ADVISE II International, Multicenter Study (ADenosine Vasodilator Independent Stenosis Evaluation II). JACC Cardiovasc Interv. 2015; 8:824–833.
94. Tonino PA, De Bruyne B, Pijls NH, et al. Fractional flow reserve versus angiography for guiding percutaneous coronary intervention. N Engl J Med. 2009; 360:213–224.
95. Deng Z, Fan Z, Lee SE, et al. Noninvasive measurement of pressure gradient across a coronary stenosis using phase contrast (PC)-MRI: a feasibility study. Magn Reson Med. 2017; 77:529–537.
96. Saloner D, Liu J, Haraldsson H. MR physics in practice: how to optimize acquisition quality and time for cardiac MR imaging. Magn Reson Imaging Clin N Am. 2015; 23:1–6.